SARS-CoV-2 Vaccine

SARS-CoV-2 Vaccine Development

SARS-CoV-2 Vaccine Research & Development, Drug Trials & Clinical Studies.


COVAC19 Blog

Serum Institute to start manufacturing Oxford University’s SARS-CoV-2 vaccine in 3 weeks; launch by October if trials succeed

Vaccine major Serum Institute of India on Sunday said it plans to start production of the Coronavirus vaccine developed by Oxford University in the next two to three weeks and hopes to bring it to the market by October if the human clinical trials are successful.

The Pune-based company has partnered with Oxford University as one of the seven global institutions manufacturing the vaccine

Oxford University scientists reveal coronavirus vaccine timeline as human trial begins

A SARS-Cov-2 vaccine being developed by Oxford University has begun human trials with the first two patients being injected with the potential vaccine.

Two volunteers were injected on Thursday, with one receiving the vaccine and the other receiving a control – a widely available meningitis vaccine, the University said. The pair will be monitored for 48 hours, before six more people enter the trial on Saturday and a larger number will join at the beginning of next week.

Pfizer and BioNTech to start human trials of Covid-19 vaccine

Berlin —Pfizer and BioNTech have secured approval for Germany’s first human clinical trials of a possible coronavirus vaccine, entering a global race to develop a defence against the pandemic.

Regulators gave the green light to test the companies’ proposed vaccine on 200 healthy people aged 18 to 55 years in a first stage, and on additional high-risk candidates in a second stage, according to a statement on Wednesday. Shares of BioNTech rose as much as 63% in Frankfurt.

New COVID-19 vaccine shows promise in monkeys. Next step: humans

An experimental Coronavirus vaccine protected monkeys from catching the viral infection, according to an unreviewed report. The new vaccine has now entered clinical trials in China to test the drug in humans.     

Although the animal study, posted April 19 to the preprint database bioRxiv, has not been subject to formal review, scientists took to Twitter to share their first impressions.

First Clinical Trial of a SARS-CoV-2 Vaccine Authorised in Germany

The Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, has authorised the first clinical trial of a SARS-CoV-2 vaccine against COVID-19 in Germany. The authorisation of this trial is the result of a careful assessment of the potential risk/benefit profile of the vaccine candidate. Based on extensive scientific advice to the medicine developer, BioNTech, in the preliminary phase, the Paul-Ehrlich-Institut was able to complete the authorisation procedure within four days. Trials of vaccine candidates in humans are an important milestone on the road to safe and efficacious vaccines against COVID-19 for the population in Germany and internationally.

Germany, UK begin human trials of experimental SARS-CoV-2 vaccine

In Britain, volunteers in a trial at the University of Oxford are set to be given on Thursday the first dose of a potential Coronavirus vaccine based on a virus found in chimpanzees.

Meanwhile on Wednesday, German regulatory body PEI green-lighted the country’s first trials on human volunteers for a Coronavirus vaccine developed by German firm Biontech and US giant Pfizer.

The Oxford trial, run by the university’s Jenner Institute, will involve 510 volunteers aged between 18 and 55 in the first phase.

Clinical Trial of SARS-CoV-2 Vaccine Begins in Seattle

The first participant in a clinical trial for a Coronavirus vaccine conducted by the Kaiser Permanente Washington Health Research Institute in Seattle will be given an experimental dose today (March 16), reports the Associated Press. The trial is being funded by the National Institutes of Health (NIH) and includes 45 young, healthy volunteers who will receive different doses of the vaccine that was co-developed by the NIH and Moderna.

Johnson & Johnson Announces a Lead SARS-CoV-2 Vaccine Candidate for Coronavirus

Johnson & Johnson and BARDA Together Commit More than $1 Billion to Novel Coronavirus Vaccine Research and Development; Company Expects to Initiate Phase 1 Human Clinical Studies of Vaccine Candidate at Latest by September 2020 Johnson & Johnson Will Establish New U.S. Vaccine Manufacturing Capabilities and Additional Production Capacity Outside the U.S. to Begin Production at Risk to Help Ensure Global Vaccine Supply

BAT working on potential SARS-CoV-2 vaccine through US bio-tech subsidiary

BAT’s US bio-tech subsidiary, Kentucky BioProcessing (KBP), is developing a potential vaccine for COVID-19 and is now in pre-clinical testing. If testing goes well, BAT is hopeful that, with the right partners and support from government agencies, between 1 and 3 million doses of the vaccine could be manufactured per week, beginning in June.

Coronavirus disease (COVID-2019) R&D

DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents. DRAFT landscape of COVID-19 candidate vaccines –11April2020

The SARS-CoV-2 vaccine development landscape

As of 8 April 2020, the global SARS-CoV-2 vaccine R&D landscape includes 115 vaccine candidates (Fig. 1), of which 78 are confirmed as active and 37 are unconfirmed (development status cannot be determined from publicly available or proprietary information sources). Of the 78 confirmed active projects, 73 are currently at exploratory or preclinical stages. The most advanced candidates have recently moved into clinical development, including mRNA-1273 from Moderna, Ad5-nCoV from CanSino Biologicals, INO-4800 from Inovio, and LV-SMENP-DC and pathogen-specific aAPC from Shenzhen Geno-Immune Medical Institute (Table 1). Numerous other vaccine developers have indicated plans to initiate human testing in 2020.